Rofleponide is a synthetic glucocorticoid corticosteroid which was never marketed.[1][2][3][4]
Clinical data | |
---|---|
Other names | 6α,9α-Difluoro-11β,16α,17α,21-tetrahydroxypregn-4-ene-3,20-dione, cyclic (R)-16,17-acetal with butyraldehyde; 16α,17α-[(1R)-butylidenebis(oxy)]-6α,9α-difluoro-11β,21-dihydroxypregn-4-ene-3,20-dione |
Drug class | Corticosteroid; Glucocorticoid |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C25H34F2O6 |
Molar mass | 468.538 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ "Rofleponide". AdisInsight.
- ^ Ahlström-Emanuelsson C, Andersson M, Persson C, Schrewelius C, Greiff L (2004). "Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis". Clin. Exp. Allergy. 34 (5): 731–5. doi:10.1111/j.1365-2222.2004.1965.x. PMID 15144464. S2CID 1480600.
- ^ K Nagaraju (30 November 2013). Manual of Pediatric Allergy. JP Medical Ltd. pp. 109–. ISBN 978-93-5090-498-5.
- ^ Jonathan A. Bernstein (27 May 2016). Rhinitis, An Issue of Immunology and Allergy Clinics of North America, E-Book. Elsevier Health Sciences. pp. 407–. ISBN 978-0-323-44468-2.